GX 623 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 135 | アイカルディ症候群 | 1 |
135. アイカルディ症候群
臨床試験数 : 1 / 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-002710-23-FR (EUCTR) | 18/06/2015 | N/A | N/A - AGS | MedDRA version: 18.0;Level: PT;Classification code 10054935;Term: Aicardi's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Zidovudine Product Name: Zidovudine Product Code: J05A F01 INN or Proposed INN: Zidovudine Other descriptive name: retrovir Trade Name: lamivudine Product Name: lamivudine Product Code: GX CJ7 INN or Proposed INN: lamivudine Other descriptive name: epivir Trade Name: Abacavir Product Name: Abacavir Product Code: GX 623 INN or Proposed INN: abacavir Other descriptive name: ziagen | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | France |